Buchumschlag

Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study

TO THE EDITOR:Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive large B-cell lymphoma (LBCL) of thymic origin occurring predominantly in young patients and accounting for 2% to 4% of non-Hodgkin lymphomas.1,2 Anti-CD19 chimeric antigen receptor T cells (CARTs) have been adopted as standar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Schubert, Maria-Luisa (VerfasserIn) , Bethge, Wolfgang A. (VerfasserIn) , Ayuk, Francis A. (VerfasserIn) , von Bonin, Malte (VerfasserIn) , Vucinic, Vladan (VerfasserIn) , Wagner-Drouet, Eva Marie (VerfasserIn) , Subklewe, Marion (VerfasserIn) , Baldus, Claudia D. (VerfasserIn) , Glass, Bertram (VerfasserIn) , Marks, Reinhard (VerfasserIn) , Mougiakakos, Dimitrios (VerfasserIn) , Schroers, Roland (VerfasserIn) , Stelljes, Matthias (VerfasserIn) , Topp, Max S. (VerfasserIn) , Wulf, Gerald (VerfasserIn) , Kröger, Nicolaus (VerfasserIn) , Dreger, Peter (VerfasserIn)
Dokumenttyp: Article (Journal) Editorial
Sprache:Englisch
Veröffentlicht: October 13, 2023
In: Blood advances
Year: 2023, Jahrgang: 7, Heft: 20, Pages: 6191-6195
ISSN:2473-9537
DOI:10.1182/bloodadvances.2023011203
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/bloodadvances.2023011203
Volltext
Verfasserangaben:Maria-Luisa Schubert, Wolfgang A. Bethge, Francis A. Ayuk, Malte von Bonin, Vladan Vucinic, Eva Marie Wagner-Drouet, Marion Subklewe, Claudia D. Baldus, Bertram Glass, Reinhard Marks, Dimitrios Mougiakakos, Roland Schroers, Matthias Stelljes, Max S. Topp, Gerald Wulf, Nicolaus Kröger, Peter Dreger, on behalf of the German Lymphoma Alliance and the German Registry for Stem Cell Transplantation
Beschreibung
Zusammenfassung:TO THE EDITOR:Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive large B-cell lymphoma (LBCL) of thymic origin occurring predominantly in young patients and accounting for 2% to 4% of non-Hodgkin lymphomas.1,2 Anti-CD19 chimeric antigen receptor T cells (CARTs) have been adopted as standard of care for the treatment of patients with relapsed and/or refractory (r/r) LBCL, including PMBCL beyond second treatment line.3,4 Axicabtagene ciloleucel (axi-cel) has been the first CART therapy specifically approved for treatment of PMBCL in this setting. However, because of the rarity of the disease, information on safety and efficacy of CARTs in PMBCL is limited.5-7 Here, we compared course and outcome of axi-cel-treatment in patients with r/r PMBCL and those with r/r diffuse LBCL (DLBCL), not otherwise specified.
Beschreibung:Gesehen am 31.01.2024
Beschreibung:Online Resource
ISSN:2473-9537
DOI:10.1182/bloodadvances.2023011203

Ähnliche Einträge